Literature DB >> 27080352

MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis.

Laurence Amar1, Charlotte Lussey-Lepoutre2, Jacques W M Lenders3, Juliette Djadi-Prat4, Pierre-Francois Plouin1, Olivier Steichen5.   

Abstract

OBJECTIVES: To systematically review the incidence and factors associated with recurrences or new tumors after apparent complete resection of pheochromocytoma or thoraco-abdomino-pelvic paraganglioma.
DESIGN: A systematic review and meta-analysis of published literature was performed.
METHODS: Pubmed and Embase from 1980 to 2012 were searched for studies published in English on patients with non-metastatic pheochromocytoma or thoraco-abdomino-pelvic paraganglioma, complete tumor resection, postoperative follow-up exceeding 1 month, and recurrence or new tumor documented by pathology, hormonal dosages, or imaging tests. Incidence rates of new events after curative surgery were calculated for each study that had sufficient information and pooled using random-effect meta-analysis.
RESULTS: In total, 38 studies were selected from 3518 references, of which 36 reported retrospective cohorts from the USA, Europe, and Asia. Patient follow-up was neither standardized nor exhaustive in the included studies. A clear description of patient retrieval methods was available for nine studies and the follow-up protocol and patient flow for four studies. Only two studies used multivariable methods to assess potential predictors of postoperative events.The overall rate of recurrent disease from 34 studies was 0.98 events/100 person-years (95% confidence interval 0.71, 1.25). Syndromic diseases and paragangliomas were consistently associated with a higher risk of a new event in individual studies and in meta-regression analysis.
CONCLUSIONS: The risk of recurrent disease after complete resection of pheochromocytoma may be lower than that previously estimated, corresponding to five events for 100 patients followed up for 5 years after complete resection. Risk stratification is required to tailor the follow-up protocol after complete resection of a pheochromocytoma or paraganglioma. Large multicenter studies are needed to this end.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2016        PMID: 27080352     DOI: 10.1530/EJE-16-0189

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

Review 1.  Pheochromocytomas and Hypertension.

Authors:  Joseph M Pappachan; Nyo Nyo Tun; Ganesan Arunagirinathan; Ravinder Sodi; Fahmy W F Hanna
Journal:  Curr Hypertens Rep       Date:  2018-01-22       Impact factor: 5.369

Review 2.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

3.  Postoperative Recurrences in Patients Operated for Pheochromocytomas and Paragangliomas: New Data Supporting Lifelong Surveillance.

Authors:  Stefanie Parisien-La Salle; Jessica Chbat; André Lacroix; Paul Perrotte; Pierre Karakiewicz; Issam Saliba; Xuan Kim Le; Harold J Olney; Isabelle Bourdeau
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

4.  From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma.

Authors:  Mirko Parasiliti-Caprino; Fabio Bioletto; Chiara Lopez; Martina Bollati; Francesca Maletta; Marina Caputo; Valentina Gasco; Antonio La Grotta; Paolo Limone; Giorgio Borretta; Marco Volante; Mauro Papotti; Anna Pia; Massimo Terzolo; Mario Morino; Barbara Pasini; Franco Veglio; Ezio Ghigo; Emanuela Arvat; Mauro Maccario
Journal:  Biomedicines       Date:  2022-06-03

Review 5.  Surgical treatment of adrenal tumors during pregnancy.

Authors:  Marisa A Bartz-Kurycki; Sophie Dream; Tracy S Wang
Journal:  Rev Endocr Metab Disord       Date:  2022-07-01       Impact factor: 9.306

6.  [Pheochromocytomatosis after adrenalectomy: metastasis or cell seeding?]

Authors:  F Weber; J Belker; N Unger; H Lahner; S Theurer; K W Schmid; D Führer; H Dralle
Journal:  Chirurg       Date:  2020-04       Impact factor: 0.955

Review 7.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

8.  Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.

Authors:  Christina Pamporaki; Barbora Hamplova; Mirko Peitzsch; Aleksander Prejbisz; Felix Beuschlein; Henri J L M Timmers; Martin Fassnacht; Barbara Klink; Maya Lodish; Constantine A Stratakis; Angela Huebner; Stephanie Fliedner; Mercedes Robledo; Richard O Sinnott; Andrzej Januszewicz; Karel Pacak; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

9.  High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Authors:  Joseph S Dillon; David Bushnell; Douglas E Laux
Journal:  Future Oncol       Date:  2021-01-28       Impact factor: 3.404

10.  Influence of secretory phenotype and preoperative preparation on surgical outcome in pheochromocytoma.

Authors:  Raluca Maria Furnica; Muhammad Muddaththir Dusoruth; Alexandre Persu; Damien Gruson; Michel Mourad; Dominique Maiter
Journal:  Endocr Connect       Date:  2021-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.